RAF/MEK
Phase 1 Completed
104 enrolled
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
151 enrolled
TACTIVE-E
Phase 1 Completed
32 enrolled
BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
Phase 1 Completed
164 enrolled 21 charts
Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)
Phase 1 Completed
11 enrolled
AZD9833
Phase 1 Completed
28 enrolled
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
96 enrolled
Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast
Phase 1 Completed
14 enrolled 12 charts
CRAD001NUS175T
Phase 1 Completed
22 enrolled
Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme
Phase 1 Completed
32 enrolled
ENCERT
Phase 1 Completed
8 enrolled
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
Phase 1 Completed
62 enrolled
ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
Phase 1 Completed
9 enrolled
A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
Phase 1 Completed
19 enrolled
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Phase 1 Completed
298 enrolled
AML1208
Phase 1 Completed
11 enrolled
Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
Phase 1 Completed
12 enrolled
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Phase 1 Completed
210 enrolled
Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
Phase 1 Completed
27 enrolled 16 charts
Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
Phase 1 Completed
18 enrolled 9 charts
Study of Everolimus (RAD001) in Combination With Lenalidomide
Phase 1 Completed
44 enrolled 9 charts
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
Phase 1 Completed
22 enrolled 16 charts
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
Phase 1 Completed
38 enrolled
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Phase 1 Completed
132 enrolled
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Phase 1 Completed
241 enrolled 31 charts
Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers
Phase 1 Completed
57 enrolled
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
Phase 1 Completed
277 enrolled
Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
Phase 1 Completed
50 enrolled
Safety of Everolimus and Pemetrexed in Lung Cancer Patients
Phase 1 Completed
48 enrolled
Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy
Phase 1 Completed
248 enrolled
Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients
Phase 1 Completed
20 enrolled
A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1 Completed
13 enrolled
Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer
Phase 1 Completed
64 enrolled
COOPERATE-1
Phase 1 Completed
36 enrolled
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Phase 1 Completed
46 enrolled
Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
Phase 1 Completed
37 enrolled
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Phase 1 Completed
79 enrolled
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
Phase 1 Completed
27 enrolled
RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer: RAD001+XELOX
Phase 1 Completed
40 enrolled
Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
Phase 1 Completed
23 enrolled 16 charts
RAP
Phase 1 Completed
43 enrolled
A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer
Phase 1 Completed
21 enrolled
Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
Phase 1 Completed
7 enrolled 17 charts
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
Phase 1 Completed
20 enrolled
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
Phase 1 Completed
13 enrolled
Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy
Phase 1 Completed
19 enrolled
A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
Phase 1 Completed
43 enrolled
Cancer
Phase 1 Completed
64 enrolled
Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma
Phase 1 Completed
26 enrolled
Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors
Phase 1 Completed
27 enrolled